CINECA IRIS Institutional Research Information System

BOSCHI, Donatella
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.811
EU - Europa 4.628
AS - Asia 1.332
AF - Africa 70
SA - Sud America 48
OC - Oceania 25
Continente sconosciuto - Info sul continente non disponibili 4
Totale 11.918
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.653
IT - Italia 1.478
CN - Cina 644
IE - Irlanda 575
SE - Svezia 522
DE - Germania 503
UA - Ucraina 273
FR - Francia 268
GB - Regno Unito 232
FI - Finlandia 178
IN - India 154
AT - Austria 144
CA - Canada 144
KR - Corea 134
DK - Danimarca 133
VN - Vietnam 108
PL - Polonia 79
HK - Hong Kong 59
BE - Belgio 49
JP - Giappone 42
SG - Singapore 42
RO - Romania 35
SN - Senegal 35
NL - Olanda 33
IR - Iran 32
TW - Taiwan 28
BR - Brasile 26
AU - Australia 23
CZ - Repubblica Ceca 19
PT - Portogallo 19
TR - Turchia 19
NG - Nigeria 17
CH - Svizzera 16
ES - Italia 14
ID - Indonesia 13
PK - Pakistan 13
MY - Malesia 12
RU - Federazione Russa 11
AR - Argentina 8
HR - Croazia 8
MX - Messico 8
GR - Grecia 7
HU - Ungheria 7
UZ - Uzbekistan 7
CL - Cile 6
IQ - Iraq 6
TH - Thailandia 6
ZA - Sudafrica 6
BG - Bulgaria 5
BZ - Belize 5
CO - Colombia 5
NO - Norvegia 5
SK - Slovacchia (Repubblica Slovacca) 5
CI - Costa d'Avorio 4
EU - Europa 4
MA - Marocco 4
EG - Egitto 3
MO - Macao, regione amministrativa speciale della Cina 3
PH - Filippine 3
RS - Serbia 3
GE - Georgia 2
LV - Lettonia 2
MK - Macedonia 2
MT - Malta 2
NZ - Nuova Zelanda 2
PE - Perù 2
SA - Arabia Saudita 2
BD - Bangladesh 1
BO - Bolivia 1
CU - Cuba 1
EE - Estonia 1
IL - Israele 1
SC - Seychelles 1
SY - Repubblica araba siriana 1
Totale 11.918
Salva come PNG Salva come JPEG
Città #
Chandler 891
Dublin 567
Ann Arbor 523
Beijing 330
Torino 285
Fairfield 269
Nyköping 241
Jacksonville 233
Ashburn 212
Houston 203
Turin 175
Woodbridge 175
Medford 155
Wilmington 152
Vienna 144
Dearborn 142
Princeton 141
Villeurbanne 125
Los Angeles 119
Redwood City 104
Seattle 104
Cambridge 97
Frankfurt am Main 86
Milan 83
Pisa 82
Fremont 76
Dong Ket 73
Warsaw 69
Ottawa 60
Boston 47
Munich 46
Brussels 42
Shanghai 41
Copenhagen 37
Boardman 34
Nanjing 34
Rome 32
New York 31
Toronto 29
Guangzhou 27
Horia 26
Washington 25
Hefei 23
Helsinki 21
Hangzhou 20
Québec 19
San Diego 19
Norwalk 18
Pune 17
Delhi 15
Verona 15
Abuja 14
Philadelphia 14
Singapore 14
Taipei 14
Falls Church 13
Menlo Park 13
Piemonte 13
Bradford 12
Central 12
Chengdu 12
Florence 12
Düsseldorf 11
Padova 11
Rivoli 11
Ypsilanti 11
Hebei 10
Jakarta 10
Naples 10
Paris 10
Bari 9
Gunzenhausen 9
Leeds 9
Leinì 9
Nürnberg 9
San Mateo 9
Shenyang 9
Alpignano 8
Amsterdam 8
Catanzaro 8
Chennai 8
Jinan 8
Kuala Lumpur 8
Lachine 8
Leawood 8
Lisbon 8
Lucknow 8
Novara 8
Phoenix 8
Siena 8
Tai Wan 8
Taichung 8
Tokyo 8
Viterbo 8
West Jordan 8
Alessandria 7
Birmingham 7
Bologna 7
Duncan 7
Mountain View 7
Totale 7.003
Salva come PNG Salva come JPEG
Nome #
Nuovi inibitori della diidroorotato deidrogenasi umana (hDHODH) e loro uso mirato sul differenziamento mieloide 418
Androgen-AR axis in primary and metastatic prostate cancer: chasing steroidogenic enzymes for therapeutic intervention 316
NOVEL HUMAN DIHYDROOROTATE DEHYDROGENASE (HDHODH) INHIBITORS AND THEIR USE IN TARGETING ONCOLOGICAL DISEASES SENSITIVE TO PYRIMIDINE STARVATION 276
DHODH inhibitors and leukemia: an emergent interest for new myeloid differentiation agents 243
PROCEEDINGS OF THE MERCK & ELSEVIER YOUNG CHEMISTSSYMPOSIUM 239
Emerging therapies for acute myeloid leukaemia using hDHODH inhibitors able to restore in vitro and in vivo myeloid differentiation 223
Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: Application of a bioisosteric scaffold hopping approach to flufenamic acid 185
Validation of a GC/MS method for the detection of two quinoline-derived selective androgen receptor modulators in doping control analysis 185
Aspects of heterocyclic chemistry in developing new 1,4-dihydropyridine Ca2+-antagonists 182
A New Synthetic Approach to Substituted β-Carboline Systems 181
Substituted 4-hydroxy-1,2,3-triazoles: synthesis, characterization and first drug design applications through bioisosteric modulation and scaffold hopping approaches 165
Hydroxytriazole derivatives as potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors discovered by bioisosteric scaffold hopping approach 161
Development of a new class of potential antiatherosclerosis agents: NO-donor antioxidants 154
Furazan and furoxan sulfonamides are strong α-carbonic anhydrase inhibitors and potential antiglaucoma agents 154
Design, synthesis, biological evaluation and X-ray structural studies of potent human dihydroorotate dehydrogenase inhibitors based on hydroxylated azole scaffolds 153
Development of Potent Human Dihydroorotate Dehydrogenase Inhibitors Able to Induces Myeloid Differentiation 149
Design, synthesis, and biological evaluation of flufenamic acid derived bioisosteres as inhibitors of aldo-keto reductase 1C3 (AKR1C3) expressed in prostate cancer 144
Nitrooxymethyl Substituted Analogues of Celecoxib: Synthesis and Pharmacological Characterization 139
Novel nitro-oxy derivatives of celecoxib for the regulation of colon cancer cell growth 139
NEW HYDROXYAZOLES INHIBITORS OF ALDO-KETO REDUCTASE 1C3 (AKR1C3) OBTAINED BY SCAFFOLD HOPPING FROM FLUFENAMIC ACID AND INDOMETHACIN FOR CASTRATE RESISTANT PROSTATE CANCER 138
Nitrooxymethyl-Substituted Analogues of Rofecoxib: Synthesis and Pharmacological Characterization 133
Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives 121
Multitarget Drugs: Synthesis and Preliminary Pharmacological Characterization of Zileuton Analogues Endowed with Dual 5-LO Inhibitor and NO-Dependent Activities 119
N-Acetyl-3-aminopyrazoles block the non canonical NF-kB cascade by selectively inhibiting NIK 117
Multitarget Drugs: Focus on the NO-donor hybrid drugs 114
New aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the hydroxytriazole scaffold 111
4-Hydroxy-N-[3,5-bis(trifluoromethyl)phenyl]-1,2,5-thiadiazole-3-carboxamide: a novel inhibitor of the canonical NF-κB cascade 109
4-Hydroxy-1,2,3-triazole moiety as bioisostere of the carboxylic acid function: a novel scaffold to probe the orthosteric γ-aminobutyric acid receptor binding site 107
Bioisosteres of Indomethacin as Inhibitors of Aldo-Keto Reductase 1C3 106
New inhibitors of Aldo-Keto Reductase 1C3 (AKR1C3) based on benzoisoxazole scaffold and their potential application in cancer 106
Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors 105
Use of Nitric Oxide Releasing Furoxan System in the Design of "Hybrids": Substitution of Furoxan Moieties for the Furan Ring in Prazosin 104
Inhibition of Human Placenta Glutathione Transferase P1-1 by the Antibiotic Calvatic Acid and its Diazocyanide Analogue: Evidence for Multiple Catalytic Intermediates 101
NO-Donor Phenols: A New Class of Products Endowed with Antioxidant and Vasodilator Properties 101
TOWARD A BIOISOSTERIC ALKAEST – APPLICATION TO THE BIOISOSTERIC MODULATION OF IMD-0354 101
In vitro myeloid differentiation using a new generation of potent human dihydroorotate dehydrogenase (hDHODH) inhibitors 100
Hydroxyazole scaffold-based Plasmodium falciparum dihydroorotate dehydrogenase inhibitors: Synthesis, biological evaluation and X-ray structural studies 98
New potential uroselective NO-donor a1-antagonists 97
Targeting Castration Resistant Prostate Cancer (CRPC) by innovative AKR1C3 inhibitors based on the 3-hydroxybenzoisoxazole structure 96
Targeting the human Dihydroorotate Dehydrogenase (hDHODH) by a Scaffold Hopping Bioisosteric approach using Hydroxylated Pentatomic Heterocycles 95
Exploration of [2 + 2 + 2] cyclotrimerisation methodology to prepare tetrahydroisoquinoline-based compounds with potential aldo-keto reductase 1C3 target affinity 94
ALPHA(1)-ADRENOCEPTOR BLOCKING ACTIVITY OF SOME RING-OPEN ANALOGS OF PRAZOSIN 93
Application of the arachno™ technology inside Educational fields: the introduction of parallel synthesis concepts inside an undergraduated lab 91
A differentiating and apoptotic therapy for Acute Myeloid Leukaemia using MEDS433, a potent human Dihydroorotate Dehydrogenase inhibitor 91
Activity of calvatic acid and its analogs against Helicobacter pylori 89
Characterisation of Furoxancarbonitriles as a New Class of Vasodilators 89
6-Cyclohexylmethoxy-5-(cyano-NNO-azoxy)pyrimidine-4-amine: A new scaffold endowed with potent CDK2 inhibitory activity 88
Towards a Bioisosteric Alkaest: application to the bioisosteric modulation of IMD-0354 87
APPLICATION OF THE ARACHNO™ TECHNOLOGY FOR THE PARALLEL SYNTHESIS OF A LIBRARY OF ASPIRIN ANALOGUES 87
Targeting the human Dihydroorotate Dehydrogenase (hDHODH) by combination of in-silico ligand/structural pharmacophore models and scaffold hopping bioisosteric approaches 86
Targeting the human Dihydroorotate Dehydrogenase (hDHODH) by a Scaffold Hopping Bioisosteric approach using Hydroxylated Pentaatomic Heterocycles 85
Inibitori della diidroorotato deidrogenasi umana (hDHODH) per l'uso come antivirali 85
Discovery and optimization of new OvCHT1 inhibitors based on the 4-hydroxy-1H-1,2,3-triazole ring 82
1H-pyrazole-4-carboxylic acids active against Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH): discovery of a new scaffold for development of antimalarial agents 81
Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold: SAR of the Biphenyl Moiety 81
Studies on New Basic NO-Donor 1,4-Dihydropyridines 80
Searching for Balanced Hybrid NO-Donor 1,4-Dihydropyridines with Basic Properties 80
Development of new hydroxypyrazole-based inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) 80
Use of the furoxan (1,2,5-oxadiazole 2-oxide) system in the design of new NO-donor antioxidant hybrids 78
NEW HYDROXYAZOLES INHIBITORS OF AKR1C3 OBTAINED FROM NSAIDS BY SCAFFOLD HOPPING APPROACH AGAINST CASTRATE RESISTANT PROSTATE CANCER 78
New Hydroxybenzoazole Inhibitors of Aldo-Keto Reductase 1C3 (AKR1C3): Disclosure of SAR Investigation to Target Prostate Cancer 77
NO-Donor Furoxans Containing a Sulphonamide Moiety and Related Furazans as Potent Carbonic Anhydrase Inhibitors 77
Use of the furoxan (1,2,5-oxadiazole 2-oxide)system in the design of new NO-donor antioxidant hybrids 76
In vitro myeloid differentiation using a new generation of potent human dihydroorotate dehydrogenase inhibitors 76
Aspects of heterocyclic chemistry in developing new 1,4-dihydropyridines Ca2+-agonists 74
Targeting Human Onchocerciasis: Recent Advances Beyond Ivermectin 74
Synthesis and Antimicrobial Activity of New 1,5-Dimethyl-3-Heteroaryl-1H-4-ONN-Azoxycyanides 73
Unsymmetrically Substituted Furoxan. Part 15. Bromination of Dimethylfuroxan and Related Compounds with NBS 71
4-Hydroxy-1H-1,2,3-Triazol-5-yl moiety as bioisoster of carboxylic group. Synthesis and pharmacological ionotropic glutamate receptors characterization of Glu analogues 71
Synthesis and Structural Characterization of Regio Substituted 4-Hydroxy-1H-1,2,3-triazols as Possible Tool in Bioisosteric Applications 71
Targeting myeloid differentiation using potent human dihydroorotate dehydrogenase (hDHODH) inhibitors 71
Emerging therapies for acute myeloid leukaemia using hDHODH inhibitors 70
Effective deploying of a novel DHODH inhibitor against herpes simplex type 1 and type 2 replication 70
A differentiating and apoptotic therapy for acute myeloid leukaemia using potent human dihydroorotate dehydrogenase inhibitors. 69
Discovery of new NIK inhibitors by Structure-Based Drug Design 68
Design of new human Dihydroorotate Dehydrogenase inhibitors: amide bioisosterism in MEDS433 optimization 68
Design, synthesis and co-crystallization of new Plasmodium falciparum dihydroorotate dehydrogenase inhibitors based on hydroxypyrazole scaffold 66
Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy 65
Structural Investigation of Ca2+ Antagonist Benzofurazanyl and Benzofuroxanyl 1,4-Dihydropyridines 64
SUBSTITUTED 4-HYDROXY-1H-1,2,3-TRIAZOLES: SYNTHESIS AND BIOISOSTERIC APPLICATIONS 64
Use of Nitric Oxide Releasing Furoxan System in the Design of Hybrids With mixed NO-like Vasodilator Activity and *1-Antagonistic Properties 63
Heterocyclic ring cleavage upon collision-induced dissociation of deprotonated 3-hydroxy-1,2,5-oxadiazoles (3-hydroxyfurazans) 63
Five-Membered N-Heterocyclic Scaffolds as Novel Amino Bioisosteres at γ-Aminobutyric Acid (GABA) Type A Receptors and GABA Transporters 63
AKR1C3 is a biomarker and druggable target for oropharyngeal tumors 63
Unsymmetrically substituted furoxans. Part 18. Smiles rearrangement in furoxan systems and in related furazans 62
Structure properties relations in the basicity and lipophilicity of arylalkylamine oxides 61
Thermolysis of 4-(2-azido-3-nitrophenyl)-1,4-dihydropyridines as source of beta-carboline derivatives and some related compounds 61
Synthesis and Voltage-Clamp Studies of Methyl 1,4-Dihydro-2,6-dimethyl-5-nitro-4-(benzofurazanyl)pyridine-3-carboxylate Racemates and Enantiomers and of their Benzofuroxanyl Analogues 61
Nitrooxymethyl substituted analogues of celecoxib as potential antitumoral drugs with reduced cardiotoxicity 60
Improvement of in vivo pharmacokinetic profile of M433, a potent and innovative hDHODH inhibitor. 59
A new pro-apoptotic therapy for Acute Myeloid Leukaemia using MEDS433, a potent human Dihydroorotate Dehydrogenase inhibitor 58
Electronic substituent effects of furoxan and furazan systems 57
The synergism between DHODH inhibitors and dipyridamole leads to metabolic lethality in acute myeloid leukemia 57
Design and synthesis of a library of pyrazolo[1,5-a]pyridine fluorophores for developing new fluorescent probes 57
Studies on Agents with Mixed NO-Dependent and Calcium Channel Antagonistic Vasodilating Activities. 56
SYNTHESIS AND PHARMACOLOGICAL EVALUATION OF NOVEL AMINO BIOISOSTERES FOR THE GABAa RECEPTOR 56
Probing salicylamide bioisosteric replacement in the design of Plasmodium Falciparum dihydroorotate dehydrogenase (pfDHODH) inhibitors 55
Hydroxypyrazolo[1,5-a]pyridine as a fluorescent carboxylic acid isostere: introducing GABAA receptor system affinities in the scaffold 52
Nitrooxymethyl substituted analogues of Celecoxib and Rofecoxib 51
The Furoxan System as a Useful Tool to Balancing "Hybrids" with mixed alfa1-Antagonist and NO-Like Vasodilator Activities 51
Totale 10.371
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.434
article - articoli 0
book - libri 0
conference - conferenze 17.571
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.005
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019297 0 0 0 0 0 0 0 0 0 0 193 104
2019/20201.648 94 63 77 149 109 244 234 100 166 163 136 113
2020/20211.412 158 103 99 89 100 72 102 64 210 96 130 189
2021/20222.026 98 65 128 201 93 84 140 99 57 213 488 360
2022/20233.174 319 346 116 296 249 734 272 202 252 93 169 126
2023/20241.412 208 219 118 100 122 190 183 82 25 158 7 0
Totale 12.331